Cardiovascular Medication Management

Introduction to Beta-Blockers

• The European Heart Journal and American College of Cardiology recommend that beta-blockers, such as bisoprolol, be used with caution when combined with other cardiovascular medications, such as digoxin and amiodarone, due to increased risk of bradycardia and conduction disturbances, and that bisoprolol has less effect on bronchial smooth muscle than non-selective beta-blockers, but still requires caution in patients with bronchospastic disease 1, 2

Drug Interactions

• The European Heart Journal and Circulation journal note that combined use of bisoprolol with non-dihydropyridine calcium channel blockers (verapamil, diltiazem) can lead to excessive bradycardia, AV conduction disorders, and hypotension, and that bisoprolol can enhance hypotensive effects when used with ACE inhibitors/ARBs and diuretics 1, 3
• The European Heart Journal warns that bisoprolol may mask symptoms of hypoglycemia (particularly tremor and tachycardia) and can prolong hypoglycemic effects of insulin in diabetic patients 4

Dosing and Titration

• The Journal of the American College of Cardiology recommends that bisoprolol be initiated at low doses (typically 1.25-2.5 mg) and gradually titrated up, with a target dose for heart failure of 10 mg once daily, and that dose titration should aim for a heart rate of 50-70 bpm 3, 2

Monitoring and Precautions

• The European Heart Journal and Circulation journal advise regular monitoring of heart rate, blood pressure, signs of heart failure exacerbation, renal function when combined with ACE inhibitors or ARBs, glucose levels in diabetic patients, and respiratory function in patients with COPD or asthma, and warn that abrupt discontinuation of bisoprolol can lead to rebound hypertension, tachycardia, and worsening angina or heart failure 3, 4

Combination Therapy with Calcium Channel Blockers

• The American Heart Association and European Society of Cardiology suggest that the combination of a non-dihydropyridine calcium channel blocker (such as verapamil or diltiazem) with a beta-blocker can be used cautiously in selected patients, particularly those with uncontrolled rapid atrial fibrillation who don't respond adequately to monotherapy with either agent, but requires careful monitoring due to potential cardiac conduction risks 5, 6
• Patients with pre-existing AV conduction disorders, sick sinus syndrome, or heart failure with reduced ejection fraction (HFrEF) should exercise caution or avoid this combination 5, 6, 7
• ECG monitoring for AV conduction abnormalities, regular heart rate and blood pressure checks, and monitoring for signs of heart failure are recommended when using this combination 5
• The European Society of Cardiology recommends starting with lower doses of both medications when using this combination, and monitoring ECG at baseline and after dose adjustments 5

• Non-dihydropyridine CCBs also inhibit P-glycoprotein and CYP3A4, potentially affecting levels of other medications including direct oral anticoagulants 5